Peanut therapy makers face pricing pushback
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
Should gene therapy patients be asked to pay?
The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…
China’s blueprint for a checkpoint blocker price war
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
Rebate ban would not necessarily equal savings, Icer says
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
The Gottlieb legacy: a surge in unproven treatments?
Many in the biopharma sector will rue the departure of Scott Gottlieb, an FDA commissioner who pursed a permissive path for novel drugs at the US regulator. Will his…
Lilly takes a leaf out of Mylan’s book to defuse insulin price complaints
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Big pharma execs decry rebates, but how big might list price cuts be?
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
Adcom gives Karyopharm a second chance with selinexor
Incredibly, a US FDA panel has left the door open for approval of Karyopharm’s selinexor in multiple myeloma, despite concerns about safety.
Xeljanz warning Jaks up safety concerns
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
